Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT03742973 |
| Consolidated Lead Sponsor | Eli Lilly and Company |
| Therapeutic Condition Cohort | Gastroenterology, Hepatology, and Renal |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | TERMINATED |
| Registered Enrollment | 2 participants (ACTUAL) |
| Registered Start Date | 2019-03-28 |
| WhyStopped Classification | Lack of Efficacy / Futility |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| UC Davis Comprehensive Cancer Center | Sacramento, CA | Open Hospital Dossier -> |
| University of Colorado Anschutz Medical Campus | Aurora, CO | Open Hospital Dossier -> |
| Henry Ford Hospital | Detroit, MI | Open Hospital Dossier -> |
| NYU Langone Health and Perlmutter Cancer Center | New York, NY | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.